Invest-NL invests in ViCentra

ViCentra is an innovative scale-up whose Kaleido insulin pump system is making impressive inroads in the market for diabetes-related medical technology. The current round of financing will enable ViCentra to pursue its plans for growth in the Netherlands. In addition, the company intends to scale up internationally in the near future and is looking across the border to Germany, France and the UK.

As an impact investor, Invest-NL aims to boost innovation and employment in Life Sciences & Health through the ViCentra transaction. Its investment will take the form of a €4 million convertible loan. Alongside Invest-NL, ViCentra’s current shareholders are acting as co-financiers in the transaction. These are the Dutch venture capital companies Inkef Capital, LSP, Health Innovations and Kreos Capital.

Invest-NL’s CEO Wouter Bos sees the ViCentra transaction as a natural choice: “This is why Invest-NL was founded: to provide innovative, high-growth Dutch companies with the venture capital they need to scale up faster. The transaction also highlights Invest-NL’s strategy of close cooperation with other financiers.”

Frans Cromme, CEO of ViCentra, is delighted with this financial injection. “This is an important step for ViCentra at a crucial time: we will use the capital to step up production, improve our product and expand commercially to other countries. Invest-NL’s decision to co-invest is a huge boost that allows us to scale up further and confirms the potential of our technology. This deal will ensure that our Kaleido insulin pump system can reach more people with type 1 diabetes and help them improve their lives.”